Evidence map›Paper›PMID 42666587›Full record

ArticleFrontiers in pharmacology2026

Novel PE-DT-fusion toxin enhances internalization and target-dependently restores the cytotoxicity of recombinant immunotoxins.

Claudia Fischer, Kerstin Wendland, Anna Ammon, Franziska Gsottberger, Lisa Mellenthin, Srdjan Petkovic, Andreas Mackensen, Fabian Müller

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Claudia FischerDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Kerstin WendlandDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Anna AmmonDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Franziska GsottbergerDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Lisa MellenthinDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Srdjan PetkovicDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Andreas MackensenDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Fabian MüllerDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recombinant immunotoxins (RITs) are fusion proteins of a targeting domain, such as an antibody fragment, and a truncated toxin, including Methods: We, therefore, generated several variants with distinct domain sequences including the catalytic (C) units of PE and DT, the furin-cleavage site of PE (fu), the transport (T) domain of DT, and the ER retention sequence KDEL. The lead candidate-a fusion of PE and DT-was combined with antibodies against CD138, CD22, glypican-3, or mesothelin. Results: This final toxin moiety was internalized 4-fold more efficiently over time on average compared to PE-based RITs, regardless of the target antigen or cell type. Improved internalization of DT over PE did not depend on a specific domain of DT. Instead, it was competed dose-dependently by poly-D lysine (PDL), indicating a more unspecific charge effect of DT over PE. The improved internalization frequently translated to enhanced cytotoxicity. Finally, combinatorial treatment with actinomycin D demonstrated synergistic effects with the lead PE-DT-fusion toxin. Conclusion: This novel and target-dependently more potent toxin moiety may provide a framework for future immunotoxin design, possibly widening the range of target antigens, including the ongoing efforts to enhance mesothelin- or CD138-targeting immunotoxins against cancer or autoimmune diseases.

Indexed as

cytotoxicitydiphtheria toxininternalizationpseudomonas exotoxinrecombinant immunotoxinssolid and hematological cancersvesicular trafficking

Identifiers

PMID42666587
PMCPMC13522408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.